Welcome to our dedicated page for Caris Life Sciences SEC filings (Ticker: CAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Caris Life Sciences, Inc. filings document financial results, governance matters, financing arrangements and material company events for an AI TechBio precision medicine business. Form 8-K disclosures report quarterly and annual operating results, molecular profiling services revenue, clinical therapy selection activity, and Regulation FD updates tied to company presentations and diagnostic-development programs.
The company’s SEC record also includes a definitive proxy statement covering annual meeting proposals, director elections and auditor ratification. Other material-event filings describe senior secured credit facilities with subsidiary guarantees, amendments to bylaws affecting shareholder derivative proceedings, and capital-structure terms relevant to Caris’ public-company reporting obligations.
Caris Life Sciences, Inc. (CAI) reports that, beginning September 14, 2026, company representatives intend to use an investor presentation in meetings with current and potential investors at the Morgan Stanley 24th Annual Global Healthcare Conference and at other investor events.
The investor presentation will be posted on the company’s investor relations website. The disclosure is furnished under Regulation FD and is expressly stated not to be “filed” or incorporated by reference for purposes of the Securities Exchange Act of 1934 or the Securities Act of 1933, except where specifically included in a future filing.
Caris Life Sciences, Inc. (CAI) reported that President David Baxley Spetzler exercised stock options for a total of 1,250,000 shares of common stock at an exercise price of $2.44 per share on September 3–4, 2026. In connection with these exercises, he sold 597,212 shares in broker-assisted sell-to-cover transactions at weighted average prices around $24.76–$25.32 to cover the aggregate exercise price and tax withholding obligations, and retained all remaining shares acquired upon exercise. The options were fully vested and were exercised before their September 12, 2026 expiration.
Caris Life Sciences, Inc. (CAI) is the issuer of common stock for which David Spetzler has filed a notice under Rule 144 to sell up to 119,212 shares through Morgan Stanley Smith Barney LLC, with an aggregate market value of $2,951,116.90 as of September 4, 2026 on NASDAQ. These shares relate to an exercise of options under a registered plan, with remarks stating the client is selling enough shares to cover the option cost and associated taxes for an expiring option. In the prior three months, David Spetzler reported a separate sale of 478,000 shares of Caris Life Sciences common stock for $11,882,984.40.
Caris Life Sciences, Inc. (CAI) reports that David Spetzler has filed a notice of proposed sale of company common stock under Rule 144. The notice covers 478,000 shares of common stock, expected to be sold on September 3, 2026 in connection with the exercise of stock options under a registered plan.
The sales are to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, with settlement in cash. Spetzler notes he is selling sufficient shares to cover the option exercise cost and related taxes for an expiring option.
Caris Life Sciences, Inc. (CAI) is the issuer of common stock that the GEORGE H POSTE REVOCABLE TRUST plans to sell under Rule 144. The notice covers a proposed sale of 100,000 shares of common stock, to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ.
The shares to be sold were acquired from the issuer through previously exercised options. The filing cites an aggregate market value of $2,606,320.00 for these 100,000 shares and lists total shares of this class outstanding as 282,595,186. The proposed sale date is 08/11/2025, with payment in cash.
Over the prior three months, George Poste reported additional sales of Caris Life Sciences common stock: 30,000 shares on 08/07/2026 for $642,633.00, and 20,000 shares on 08/03/2026 for $325,000.00. The notice is signed by George Poste, Trustee.
Caris Life Sciences director Peter M. Castleman reported an acquisition of 13,192 shares of Common Stock on 2026-08-14, as an award of restricted stock units that vest in accordance with the applicable grant agreement, bringing his directly held shares to 29,321.
He also reports indirect ownership of 108,009 shares held by a family trust and 10,546,384 shares held by CLS-PF-SPE, LLC, where he has voting and investment power through a manager role and disclaims beneficial ownership except to the extent of his pecuniary interest.
PHILLIPS T DANNY reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences, Inc. director Phillips T. Danny received an equity award reported as 13,192 shares of Common Stock, reflected as a grant or award of restricted stock units. The award was at a stated price of $0.00 per share and increased his direct holdings to 133,060 shares. The restricted stock units vest in accordance with the applicable grant agreement.
Minor Lloyd reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences, Inc. reported that director Lloyd Minor received a grant of 13,192 shares of Common Stock in the form of restricted stock units on 2026-08-14 at a stated price of $0.00 per share. These restricted stock units vest in accordance with the applicable grant agreement. Following this award, Minor directly holds 31,813 shares of the company’s Common Stock.
Caris Life Sciences, Inc. reported that director Joseph E. Gilliam received an equity award in the form of 13,192 shares of Common Stock on 2026-08-14, recorded as a grant or award acquisition at no cash price per share. Following this award, his directly held position increased to 29,321 shares. A footnote explains that the award consists of restricted stock units that vest in accordance with the applicable grant agreement.
Caris Life Sciences, Inc. reported that director David Paul Fredrickson received an equity compensation award. He acquired 13,192 shares of Common Stock on August 14, 2026, at a stated price of $0.00 per share, representing an award of restricted stock units that vest under the applicable grant agreement. Following this award, his directly held Common Stock position increased to 31,813 shares.